SEAWEEDS

Seaweeds including wakame and kombu bring active compounds including fucoxanthin and fucodian. The most compelling study uses a powdered supplement for in advanced colorectal cancer. These patients saw a tendency towards half the relative risk for progression, but the small size of the cohort means there the data did not reach statistical certainty

There are pilot trials in breast cancer reporting suppression of inflammatory markers such as IL-1β, associated with cancer progression. However, these reports find the benefits so far are increased tolerance for chemotherapy and some improved quality of life metrics

Secondary actions contribute to gut microbiota diversity and have been shown to benefit metabolic health in some research

EXAMPLES OF IMPROVED OUTCOMES

SOME

PRE-DIAGNOSIS OR PREVENTION

NO

Highlighted Studies

To the best of our knowledge, this is the first clinical trial evaluating the efficacy of fucoidan. In our study, the patients in the study group received 4 g of LMF BID powder for six months. The results reveal that the DCR was significantly higher, with an increase of 23.6% for the study group when compared to the control group. Moreover, the ORR tended to be insignificantly higher in the study group when compared to the control group. A trend of improved OS and PFS was also noted in our an...

Link

Studies have demonstrated that seaweeds and their bioactive components are potential foods that can be used to manage human metabolic syndrome, and that they have positive effects on obesity, hyperglycemia, hyperlipidemia, and hypertension. Animal experiments have shown that seaweed-derived bioactive components can decrease the risk of metabolic syndrome-related diseases by reducing the Firmicutes/Bacteroidetes ratio, increasing the relative abundance of beneficial bacteria, such as Bacteroid...

Link

This exploratory prospective clinical study for advanced cancer patients revealed that levels of important proinflammatory cytokines, including IL-1β, IL-6, and TNF-α, were significantly reduced after a short period of fucoidan administration. Interestingly, a subgroup analysis showed that the responsiveness of IL-1β was significantly correlated with the overall survival and suggested that this responsiveness might be a useful prognostic biomarker for advanced cancer patients receiving fuc...

Link

In the present study, although the number of patients was limited and the results were not statistically significant, the prognosis of patients with unresectable advanced or recurrent colorectal cancer was more favorable upon treatment with fucoidan than without. This may be explained by the fact that fucoidan prolonged the duration of the chemotherapy by suppressing the toxicity of the anti-cancer drugs or through an anti-cancer effect of fucoidan itself. Therefore, large controlled studies ...

Link
BACK TO INDEX

Help grow the evidence. Login for online forms or try Feedback and Ideas below.

TABLE OF REFERENCES

URLHighlightHighlight 2Visuals (click)
https://www.sciencedirect.com/science/article/abs/pii/S0378874120331846Collectively, our findings suggested that FX suppresses metastasis of lung cancer cells and overcomes EGFR TKIs resistance. Thus, FX is worthy of further investigation as a drug candidate for the treatment of lung cancer.we demonstrated that FX inhibited lung cancer cells metastasis in vivo. The anti-metastatic effects of FX on lung cancer cells might be attributed to inhibition of EMT and PI3K/AKT/NF-κB pathway. We further demonstrated that the anti-tumor activity of FX was not only limited to the drug sensitive cell lines, but also prominent on lung cancer cells with Gef resistant phenotyp
https://www.mdpi.com/2072-6643/15/23/4987In this meta-analysis, postprandial blood glucose, glycated hemoglobin (HbA1c), and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) levels demonstrated significant improvements in the seaweed group compared to the control group. Conversely, fasting blood glucose and insulin levels did not show significant associations with seaweed consumption. Subgroup analysis revealed that a high dose (1000 mg or more) was more beneficial than a low dose, and seaweeds such as Laminaria digitata, Undaria pinnatifida, Acophyllum nodosum, and Fucus vesiculosus were found to be more effective at improving blood glucose levels than control treatments. Therefore, based on our research, seaweed supplementation appears to be a promising strategy for reducing postprandial blood glucose, HbA1c, and HOMA-IR levels, thereby enabling better blood glucose management and leading to a decreased risk of type 2 diabetes.The decrease in postprandial blood glucose, HbA1c, and HOMA-IR as a result of consuming seaweed or its extracts indicates a reduced risk of diabetes patients experiencing post-meal hyperglycemia and signifies an improvement in blood sugar management and metabolic status. In the subgroup analysis of this study, differences were observed based on factors such as duration, dosage, and scientific names. Concerning the duration, a significant reduction in HOMA-IR was noted in the group with a consumption period of less than 12 weeks, while fasting blood glucose and HbA1c significantly decreased in the group with a consumption period exceeding 12 weeks. Additionally, it was observed that the majority of biomarkers improved when the daily intake exceeded 1000 mg. These findings highlight the promising role of seaweed consumption in enhancing glycemic control.
https://www.spandidos-publications.com/10.3892/ol.2011.254 In the present study, although the number of patients was limited and the results were not statistically significant, the prognosis of patients with unresectable advanced or recurrent colorectal cancer was more favorable upon treatment with fucoidan than without. This may be explained by the fact that fucoidan prolonged the duration of the chemotherapy by suppressing the toxicity of the anti-cancer drugs or through an anti-cancer effect of fucoidan itself. Therefore, large controlled studies are required to evaluate the therapeutic effect of fucoidan for unresectable advanced or recurrent colorectal cancer.We found that fucoidan suppressed the occurrence of general fatigue in colorectal cancer patients during chemotherapy. It has been demonstrated that fatigue reduces the individual resources of patients, affects their nutritional status, increases morbidity and can have a negative impact on the dose intensity of cancer therapy (16). Iop et al (16) reported that fatigue, which was graded using NCI CTC, was detected in almost 30% of patients receiving chemotherapy. In the present study, grade 2 and 3 fatigue was detected in 60% of colorectal cancer patients during chemotherapy.
https://journals.sagepub.com/doi/10.1177/1534735417692097This exploratory prospective clinical study for advanced cancer patients revealed that levels of important proinflammatory cytokines, including IL-1β, IL-6, and TNF-α, were significantly reduced after a short period of fucoidan administration. Interestingly, a subgroup analysis showed that the responsiveness of IL-1β was significantly correlated with the overall survival and suggested that this responsiveness might be a useful prognostic biomarker for advanced cancer patients receiving fucoidan. To the best of our knowledge, this is the first study to provide evidence of the anti-inflammatory effects of fucoidan for advanced cancer patientsTo explore the predictive biomarkers in relation to the clinical responsiveness to fucoidan, a subgroup analysis was conducted between the overall survival (from the start of fucoidan administration) and the response of inflammatory biomarkers. Remarkably, univariate analyses with log-rank tests demonstrated that the patients whose IL-1β level decreased during the first 2 weeks (IL-1β responders) had a significantly longer survival rate compared with the prognoses for IL-1β nonresponders (median survival time = 13.0 vs 5.0 months)
https://pubmed.ncbi.nlm.nih.gov/25748372/Fucoxanthin, a specific carotenoid in brown algae, has garnered much attention for its anti-obesity and anti-diabetic effects attributable to a unique mechanism. Fucoxanthin induces uncoupling protein 1 (UCP1) expression in white adipose tissue. That inner membrane mitochondrial protein, UCP1, can dissipate energy through oxidation of fatty acids and heat production. Furthermore, fucoxanthin improves insulin resistance and ameliorates blood glucose levels through down-regulation of adipocytokines related to insulin resistanceThese results suggest that fucoxanthin is safe as a component of functional foods in common toxicity assay. Additionally, in eastern Asian coun- tries, sea algae（Wakame, Laminaria）have been consumed as edible algae for centuries...Fucoxanthin has a strong effect on re- solving metabolic syndrome problems. That unique effect has not been reported for any other food component. Fu- coxanthin in algae is useful as a new functional food from sea products
https://www.researchgate.net/publication/318507817_Seaweed_Fucoxanthin_Supplementation_Improves_Obesity_Parameters_in_Mild_Obese_Japanese_SubjectsIn the present clinical study, ingestion of fucoxanthin at 3 mg/day significantly decreased the body weight, BMI, and visceral fat area compared to placebo. Thus, fucoxanthin was discovered to suppress body weight and BMI by reducing visceral fatIn this study, we demonstrated that a 4-week treatment with fucoxanthin (3 mg/day) reduced body weight, BMI and abdominal fats. Therefore, we discovered that fucoxanthin has weight loss effects in mildly obese adults.
https://www.mdpi.com/2072-6643/16/7/1041Our findings suggest that adequate seaweed consumption may offer protection against TC in the Korean population, and appropriate dairy product intake could be advantageous in reducing its incidence, potentially enhancing dietary habits for TC prevention in this population. In future research, collecting prospective data from large cohorts and conducting clinical studies that assess the influence of different iodine-rich foods on TC risk by measuring urinary iodine concentrations is imperative.The exact reason for this relationship remains unknown; however, seaweed is not only rich in iodine but also contains various vitamins, minerals, dietary fibers, and flavonoids, considered preventive agents against lifestyle-related diseases [27]. Therefore, the effect of seaweed on TC is influenced by the interaction of various nutrients. Further research, including observational and interventional studies, is necessary to gain a comprehensive understanding of the influence of seaweed on TC
https://www.mdpi.com/1660-3397/15/4/122 To the best of our knowledge, this is the first clinical trial evaluating the efficacy of fucoidan. In our study, the patients in the study group received 4 g of LMF BID powder for six months. The results reveal that the DCR was significantly higher, with an increase of 23.6% for the study group when compared to the control group. Moreover, the ORR tended to be insignificantly higher in the study group when compared to the control group. A trend of improved OS and PFS was also noted in our analysis. Additional studies with a larger sample size should be conducted to evaluate whether LMF eventually improves OS and PFS.This is the first randomized, double-blind, controlled trial evaluating the efficacy of LMF as a supplemental therapy in patients with mCRC. Our study results demonstrate the advantages of LMF in improving the disease control rate (DCR). We believe that this study can provide insights into the development of cancer treatments, particularly in the combination of natural or herbal products with chemotarget agents.

Help grow the community

Join the Pubmedders subscriber base

Get our monthly email newletter – designed so you can give us your opinions, thoughts and feedback…

ALL contributions are invested into growing the site to help others.